CNS Drugs

, Volume 26, Issue 9, pp 733–759 | Cite as

Body Weight and Metabolic Adverse Effects of Asenapine, Iloperidone, Lurasidone and Paliperidone in the Treatment of Schizophrenia and Bipolar Disorder

A Systematic Review and Exploratory Meta-Analysis
  • Marc De Hert
  • Weiping Yu
  • Johan Detraux
  • Kim Sweers
  • Ruud van Winkel
  • Christoph U. Correll
Systematic Review


Background: The introduction of second-generation antipsychotics (SGAs) over the past 2 decades generated considerable optimism that better anti-psychotic treatments for schizophrenia and bipolar disorder were possible. SGAs offer several tolerability benefits over first-generation antipsychotics (FGAs), particularly with respect to extrapyramidal symptoms. However, SGAs can induce serious metabolic dysregulations, especially in drug-naive, first-episode, and child and adolescent populations, with olanzapine and clozapine having the highest propensity to cause these abnormalities. In this context, newer SGAs were developed to further improve the adverse effect burden of available agents. However, until now, the metabolic risk profile of the newly approved SGAs — asenapine, iloperidone, lurasidone and paliperidone (paliperidone extended release and paliperidone palmitate) — has not been compared.

Objective: The objective of this systematic review and exploratory meta-analysis was to assess the effects of asenapine, iloperidone, lurasidone and paliperidone on body weight and other metabolic parameters (cholesterol, triglycerides and glucose), as this information is relevant to guide clinical decision making.

Method: A systematic literature search (1966–March 2012), using the Cochrane Central Register of Controlled Trials and MEDLINE, CINAHL and EMBASE databases, was conducted for randomized, placebo-controlled and head-to-head clinical trials of asenapine, iloperidone, lurasidone and paliperidone. Published and unpublished data on changes in body weight and glucose and lipid metabolism parameters were extracted. For placebo-controlled, short-term (≤12 weeks) and longer-term (>12 weeks) trials with available data on ≥7% weight increase compared with pre-treatment weight, or mean weight change with standard deviation, a formal meta-analysis was performed, estimating the pooled effect size (represented as relative risk [RR], numbers-needed-to-harm [NNH] and weighted mean difference [WMD]). An exploratory meta-analysis was also performed for the other metabolic variables (cholesterol, triglycerides and glucose). Data from active- and placebo-controlled studies were used for a pooled comparison of simple mean changes in weight, cholesterol, triglyceride and glucose levels.

Results: Fifty-six trials (n = 21691) in schizophrenia (N = 49, n= 19 299) or bipolar disorder (N = 7, n = 2392) were identified (asenapine: N = 9, iloperidone: N=11, lurasidone: N = 8, paliperidone: N = 28). Most of the trials (64.3%) were of ≤12 weeks’ duration. In the short-term trials, compared with placebo, a ≥7% weight increase was statistically significantly (p < 0.05) most prevalent for asenapine (5 trials, n = 1360, RR = 4.09, 95% confidence interval [CI] 2.25, 7.43, NNH = 17), followed by iloperidone (4 trials, n = 1931, RR = 3.13, 95% CI 2.08, 4.70, NNH = 11) and paliperidone (12 trials, n = 4087, RR = 2.17, 95% CI 1.64, 2.86, NNH = 20). The effect of lurasidone on body weight (6 trials, n = 1793, RR = 1.42, 95% CI 0.87, 2.29) was not statistically significant. Short-term weight gain was statistically significantly (p < 0.001) greater than placebo with iloperidone (1 trial, n = 300, +2.50 kg, 95% CI 1.92, 3.08), paliperidone (15 trials, n = 3552, +1.24 kg, 95% CI 0.91, 1.57), asenapine (3 trials, n = 751, +1.16 kg, 95% CI 0.83, 1.49), as well as with lurasidone (5 trials, n = 999, +0.49 kg, 95% CI 0.17, 0.81, p < 0.01). Sufficient meta-analysable, longer-term, weight change data were only available for asenapine and paliperidone, showing statistically significantly (p < 0.001) greater weight gain versus placebo for both drugs (asenapine, 3 trials, n = 311, +1.30 kg, 95% CI 0.62, 1.98; paliperidone, 6 trials, n = 1174, +0.50 kg, 95% CI 0.22, 0.78). Although statistically significant, in general, no clinically meaningful differences were observed between the four newly approved SGAs and placebo regarding the mean change from baseline to endpoint in cholesterol levels in short-term trials, with the exception of iloperidone for total cholesterol (1 trial, n = 300, +11.60 mg/dL, 95% CI 4.98, 18.22, p ≤ 0.001), high-density cholesterol (1 trial, n = 300, +3.6 mg/dL, 95% CI 1.58, 5.62, ps < 0.001) and low-density cholesterol (1 trial, n = 300, +10.30 mg/dL, 95% CI 4.94, 15.66, p < 0.001) and with the exception of lurasidone for high-density cholesterol (5 trials, n = 1004, +1.50 mg/dL, 95% CI 0.56, 2.44, p < 0.01). Asenapine increased total cholesterol statistically significantly (p < 0.05) during longer-term treatment (1 trial, n = 194, +6.53 mg/dL, 95% CI 1.17, 11.89). Regarding triglycerides, only short-term (3 trials, n = 1152, +1.78 mg/dL, 95% CI 0.40, 3.17, p < 0.01) and longer-term treatment with paliperidone (4 trials, n = 791, −0.20 mg/dL, 95% CI −0.40, −0.01, p < 0.05) had a statistically, but not clinically, significant effect. Statistically significant changes in glucose levels were noticed during short-term treatment with asenapine (2 trials, n = 379, −3.95 mg/dL, 95% CI −7.37, −0.53, p < 0.05) and iloperidone (1 trial, n =300, +6.90 mg/dL, 95% CI 2.48, 11.32, p < 0.01), and during long-term treatment with paliperidone (6 trials, n = 1022, +3.39 mg/dL, 95% CI 0.42, 6.36, p < 0.05).

Conclusion: While preliminary data suggest the lowest weight gain potential with lurasidone and potentially relevant short-term metabolic effects for asenapine and iloperidone, data are still too sparse to comprehensively evaluate the metabolic safety of the newly approved SGAs. Therefore, there is a clear need for further controlled studies to evaluate whether these agents are less problematic regarding treatment-emergent weight gain and metabolic disturbances than other currently available antipsychotics.


Clozapine Risperidone Olanzapine Quetiapine Aripiprazole 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Marc De Hert declares that he has been a consultant for, received grant and/or research support and honoraria from, and been on the speakers’ bureaus and/or advisory boards of the following companies: Astra Zeneca, Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Lundbeck, Pfizer and Sanofi Aventis. He declares associations with the following companies: Astra Zeneca, Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Lundbeck, Pfizer and Sanofi Aventis.

Ruud van Winkel declares that he has received unrestricted grants from Astra Zeneca and Eli Lilly.

Christoph Correll declares that he has been a consultant and/or advisor for or has received honoraria from the following companies: Actelion, Alexza, AstraZeneca, Biotis, Boehringer-Ingelheim, Bristol-Myers Squibb, Cephalon, Desitin, Eli Lilly, GlaxoSmithKline, Hoffmann-La Roche, IntraCellular Therapies, Lundbeck, MedAvante, Medicure, Merck, Novartis, Otsuka, Ortho-McNeill-Janssen, Pfizer, ProPhase, Schering-Plough, Sunovion, Supernus, Takeda, Teva and Vanda. He also has received grants from the National Institute of Mental Health, the American Academy of Child and Adolescent Psychiatry and the National Alliance for Research in Schizophrenia and Depression, Bristol-Myers Squibb, Otsuka and Janssen/J&J.

Weiping Yu, Johan Detraux and Kim Sweers have no conflicts of interest.

No sources of funding were used to conduct this study and/or to prepare the review.


  1. 1.
    McDonagh M, Peterson K, Carson S, et al. Drug class review: atypical antipsychotic drugs: final update 3 report. Portland (OR): Oregon Health & Science University, 2010 JulGoogle Scholar
  2. 2.
    Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 2010 Sep; 79(9): 1115–24CrossRefGoogle Scholar
  3. 3.
    De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with anti-psychotic drugs. Nat Rev Endocrinol 2012; 8: 114–26CrossRefGoogle Scholar
  4. 4.
    De Hert M, Dobbelaere M, Sheridan EM, et al. Metabolic and endocrine adverse effects of second-generation anti-psychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 2011 Apr; 26(3): 144–58PubMedCrossRefGoogle Scholar
  5. 5.
    Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 2010 Jun; 35(7): 1520–30PubMedCrossRefGoogle Scholar
  6. 6.
    Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med 2011 Feb; 17(2): 97–107PubMedCrossRefGoogle Scholar
  7. 7.
    De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders: I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011 Feb; 10(1): 52–77Google Scholar
  8. 8.
    Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009 Jan 3; 373(9657): 31–41PubMedCrossRefGoogle Scholar
  9. 9.
    Rummel-Kluge C, Komossa K, Schwarz S, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull 2012 Jan; 38(1): 167–77PubMedCrossRefGoogle Scholar
  10. 10.
    Parsons B, Allison DB, Loebel A, et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res 2009 May; 110(1–3): 103–10PubMedCrossRefGoogle Scholar
  11. 11.
    Coccurello R, Moles A. Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol Ther 2010 Sep; 127(3): 210–51PubMedCrossRefGoogle Scholar
  12. 12.
    Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008 Mar 29; 371(9618): 1085–97PubMedCrossRefGoogle Scholar
  13. 13.
    Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 Suppl. 1: 1–93PubMedGoogle Scholar
  14. 14.
    Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 Sep 22; 353(12): 1209–23PubMedCrossRefGoogle Scholar
  15. 15.
    Citrome L. Risk-benefit analysis of available treatments for schizophrenia. Psychiatric Times 2007; 1: 27–30Google Scholar
  16. 16.
    Tarricone I, Ferrari Gozzi B, Serretti A, et al. Weight gain in antipsychotic-naive patients: a review and meta-analysis. Psychol Med 2010 Feb; 40(2): 187–200PubMedCrossRefGoogle Scholar
  17. 17.
    Alvarez-Jiménez M, González-Blanch C, Crespo-Facorro B, et al. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs 2008; 22(7): 547–62PubMedCrossRefGoogle Scholar
  18. 18.
    Strassnig M, Miewald J, Keshavan M, et al. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr Res 2007 Jul; 93(1–3): 90–8PubMedCrossRefGoogle Scholar
  19. 19.
    Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009 Oct 28; 302(16): 1765–73PubMedCrossRefGoogle Scholar
  20. 20.
    Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment: pharmacological mechanisms. Pharmacol Ther 2010 Jan; 125(1): 169–79PubMedCrossRefGoogle Scholar
  21. 21.
    Pringsheim T, Lam D, Ching H, et al. Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. Drug Saf 2011; 34(8): 651–68PubMedCrossRefGoogle Scholar
  22. 22.
    Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010 Nov; 123(2–3): 225–33PubMedCrossRefGoogle Scholar
  23. 23.
    Meyer JM, Davis VG, McEvoy JP, et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res 2008 Aug; 103(1–3): 104–9PubMedCrossRefGoogle Scholar
  24. 24.
    Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008 Nov; 165(11): 1420–31PubMedCrossRefGoogle Scholar
  25. 25.
    Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology 2010 Aug; 35(9): 1997–2004PubMedCrossRefGoogle Scholar
  26. 26.
    Citrome L. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics. Postgrad Med 2011 Mar; 123(2): 153–62PubMedCrossRefGoogle Scholar
  27. 27.
    Howland RH. Update on newer antipsychotic drugs. J Psychosoc Nurs Ment Health Serv 2011 Apr; 49(4): 13–5CrossRefGoogle Scholar
  28. 28.
    Meltzer HY, Bobo WV, Nuamah IF, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 2008 May; 69(5): 817–29PubMedCrossRefGoogle Scholar
  29. 29.
    Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007 Dec 15; 62(12): 1363–70PubMedCrossRefGoogle Scholar
  30. 30.
    Olivo SA, Macedo LG, Gadotti IC, et al. Scales to assess the quality of randomized controlled trials: a systematic review. Phys Ther 2008 Feb; 88(2): 156–75PubMedCrossRefGoogle Scholar
  31. 31.
    Hayashino Y, Noguchi Y, Fukui T. Systematic evaluation and comparison of statistical tests for publication bias. J Epidemiol 2005 Nov; 15(6): 235–43PubMedCrossRefGoogle Scholar
  32. 32.
    Calabrese JR, Stet L, Kothari H, et al. Asenapine as adjunctive treatment for bipolar mania: results of a placebo-controlled 12-week study and 40-week extension. American Psychiatric Association’s 62nd Institute on Psychiatric Services; 2010 Oct 14–17; Boston (MA)Google Scholar
  33. 33.
    Kane JM, Cohen M, Zhao J, et al. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol 2010 Apr; 30(2): 106–15PubMedCrossRefGoogle Scholar
  34. 34.
    McIntyre RS, Cohen M, Zhao J, et al. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord 2010 Apr; 122(1–2): 27–38PubMedCrossRefGoogle Scholar
  35. 35.
    McIntyre RS, Cohen M, Zhao J, et al. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 2009 Nov; 11(7): 673–86PubMedCrossRefGoogle Scholar
  36. 36.
    Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry 2007 Oct; 68(10): 1492–500PubMedCrossRefGoogle Scholar
  37. 37.
    Kane JM, Mackle M, Snow-Adami L, et al. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry 2011; 72(3): 349–55PubMedCrossRefGoogle Scholar
  38. 38.
    McIntyre RS, Cohen M, Zhao J, et al. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord Nov 2010; 126(3): 358–65CrossRefGoogle Scholar
  39. 39.
    Schoemaker J, Naber D, Vrijland P, et al. Long-term assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry 2010; 43(4): 138–46PubMedCrossRefGoogle Scholar
  40. 40.
    Cutler AJ, Kalali AH, Weiden PJ, et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute acute exacerbations of schizophrenia. J Clin Psychopharmacol 2008 Apr; 28 (2 Suppl. 1): S20–8PubMedCrossRefGoogle Scholar
  41. 41.
    FDA. Drug approval package: Fanapt® (iloperidone) tablets, 27 July 2008 [online]. Available from URL: [Accessed 2012 Feb 6]
  42. 42.
    Kane JM, Lauriello J, Laska E, et al. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol 2008 Apr; 28 (2 Suppl. 1): S29–35PubMedCrossRefGoogle Scholar
  43. 43.
    Nasrallah HA, Weiden P, Citrome L, et al. The metabolic profile of iloperidone compared to ziprasidone in a short-term, placebo-controlled clinical trial and 25-week, a open-label extension. American College of Neuropyschopharmacology; 2010 Dec 5–9; Miami Beach (FL)Google Scholar
  44. 44.
    Potkin S, Ogasa M, Cucchiaro J, et al. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr Res 2011; 132(2–3): 101–7PubMedCrossRefGoogle Scholar
  45. 45.
    FDA. Drug approval package: Latuda® (lurasidone hydrochloride) tablets, 3 December 2010 [online]. Available from URL: [Accessed 2012 Feb 6]
  46. 46.
    Loebel A, Cucchiaro J, Sarma K, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled study (PEARL 3). American College of Neuropsychopharmacology; 2010 Dec 5–9; Miami Beach (FL)Google Scholar
  47. 47.
    Citrome L, Cucchiaro J, Sarma K, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol 2012 May; 27(3): 165–76PubMedCrossRefGoogle Scholar
  48. 48.
    Berwaerts J, Lane R, Nuamah IF, et al. Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study. J Affect Disord 2011; 129: 252–60PubMedCrossRefGoogle Scholar
  49. 49.
    Invega® (paliperidone) extended-release tablets [package insert]. Titusville (NJ): Ortho-McNeil Neurologics, Inc., 2007 AprGoogle Scholar
  50. 50.
    Singh J, Robb A, Vijapurkar U, et al. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biol Psychiatry 2011; 70: 1179–87PubMedCrossRefGoogle Scholar
  51. 51.
    Canuso CM, Lindenmayer JP, Kosik-Gonzalez C, et al. A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. J Clin Psychiatry 2010 May; 71(5): 587–98PubMedCrossRefGoogle Scholar
  52. 52.
    Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2010 Feb; 116(2–3): 107–17PubMedCrossRefGoogle Scholar
  53. 53.
    Vieta E, Nuamah IF, Lim P, et al. A randomized, placebo-and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord 2010; 12: 230–43PubMedCrossRefGoogle Scholar
  54. 54.
    Canuso CM, Dirks B, Carothers J, et al. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry 2009 Jun; 166(6): 691–701PubMedCrossRefGoogle Scholar
  55. 55.
    Schreiner A, Badescu GM, Jukic V, et al. Safety, tolerability and treatment response of flexible doses of paliperidone ER in acutely exacerbated patients with schizophrenia (Pertain) [poster]. World Psychiatry Association; 2009 Apr 1–4; FlorenceGoogle Scholar
  56. 56.
    Tzimos A, Samokhvalov V, Kramer M, et al. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry 2008 Jan; 16(1): 31–43PubMedCrossRefGoogle Scholar
  57. 57.
    Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007; 93(1–3): 117–30PubMedCrossRefGoogle Scholar
  58. 58.
    Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007 Feb; 90(1–3): 147–61PubMedCrossRefGoogle Scholar
  59. 59.
    Gopal S, Vijapurkar U, Lim P, et al. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol 2011 May; 25(5): 685–97PubMedCrossRefGoogle Scholar
  60. 60.
    Alphs L, Bossie CA, Sliwa JK, et al. Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial. Ann Gen Psychiatry 2011; 10(12): 1–10Google Scholar
  61. 61.
    Everitt J, Rey JA. Medication use evaluation: metabolic side effects of paliperidone in an inpatient psychiatric facility. 13th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists; 2010 Apr 18–21; San Antonio (TX)Google Scholar
  62. 62.
    Li H, Rui Q, Ning X. A comparative randomized, open-label, rater-blinded study of paliperidone palmitate and risperidone long acting injectable therapy in patients with schizophrenia. Poster presented at the 27th International College of Neuropsychopharmacology Congress; 2010 Jun 6–10; Hong KongGoogle Scholar
  63. 63.
    Nasrallah HA, Gopal S, Gassmann-Mayer C, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 2010 Sep; 35(10): 2072–82PubMedCrossRefGoogle Scholar
  64. 64.
    Pandina GJ, Lindenmayer JP, Lull J, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 2010 Jun; 30(3): 235–44PubMedCrossRefGoogle Scholar
  65. 65.
    Schreiner A, Tessier C, Hoeben D, et al. A flexible-dose study of paliperidone ER in non-acute patients with schizophrenia previously unsuccessfully treated with other oral antipsychotics [poster]. 18th European Congress of Psychiatry; 2010 Feb 27–Mar 2; MunichGoogle Scholar
  66. 66.
    Emsley R, Berwaerts J, Eerderkens M, et al. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharm 2008; 23(6): 343–56CrossRefGoogle Scholar
  67. 67.
    Kramer M, Simpson G, Maciulis V. Oral paliperidone extended-release treatment: long-term metabolic outcomes in patients with schizophrenia [poster]. WWS; 2008 Feb 3–7; MontreuxGoogle Scholar
  68. 68.
    Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2007 Feb; 27(1): 6–14PubMedCrossRefGoogle Scholar
  69. 69.
    Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract 2009 Dec; 63(12): 1762–84PubMedCrossRefGoogle Scholar
  70. 70.
    Weber J, McCormack PL. Asenapine. CNS Drugs 2009 Sep 1; 23(9): 781–92PubMedCrossRefGoogle Scholar
  71. 71.
    Emsley RA, Schoemaker JH, Vrijland P, et al. Long-term safety of asenapine versus olanzapine in patients with schizophrenia or schizoaffective disorder [abstract no. 323]. 21st Annual US Psychiatric and Mental Health Congress; 2008 Oct 30–Nov 1; San Diego (CA)Google Scholar
  72. 72.
    Citrome L, Nasrallah HA. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opin Pharmacother 2012 Aug; 13(11): 1599–613PubMedCrossRefGoogle Scholar
  73. 73.
    Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003 Mar; 28(3): 519–26PubMedCrossRefGoogle Scholar
  74. 74.
    Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent?. A literature review. J Clin Psychiatry 2009 Jul; 70(7): 1041–50PubMedCrossRefGoogle Scholar
  75. 75.
    Kim SF, Huang AS, Snowman AM, et al. From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A 2007 Feb 27; 104(9): 3456–9PubMedCrossRefGoogle Scholar
  76. 76.
    Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 2011 Feb; 11(1): 59–67PubMedCrossRefGoogle Scholar
  77. 77.
    Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract 2011 Feb; 65(2): 189–210PubMedCrossRefGoogle Scholar
  78. 78.
    Thompson A, Lavedan C, Volpi S. Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone. Psychiatry Res 2010 Feb 28; 175(3): 271–3PubMedCrossRefGoogle Scholar
  79. 79.
    Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs 2008; 68(16): 2269–92PubMedCrossRefGoogle Scholar
  80. 80.
    Reynolds GP, Zhang Z, Zhang X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry 2003 Apr; 160(4): 677–9PubMedCrossRefGoogle Scholar
  81. 81.
    Miller DD, Ellingrod VL, Holman TL, et al. Clozapine-induced weight gain associated with the 5HT2C receptor −759C/T polymorphism. Am J Med Genet B Neuropsychiatr Genet 2005 Feb 5; 133B(1): 97–100PubMedCrossRefGoogle Scholar
  82. 82.
    Ellingrod VL, Perry PJ, Ringold JC, et al. Weight gain associated with the −759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet 2005 Apr 5; 134B(1): 76–8PubMedCrossRefGoogle Scholar
  83. 83.
    Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002 Jun 15; 359(9323): 2086–7PubMedCrossRefGoogle Scholar
  84. 84.
    Templeman LA, Reynolds GP, Arranz B, et al. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 2005 Apr; 15(4): 195–200PubMedCrossRefGoogle Scholar
  85. 85.
    Johnson DE, Nedza FM, Spracklin DK, et al. The role of muscarinic receptor antagonism in antipsychotic-induced hippocampal acetylcholine release. Eur J Pharmacol 2005 Jan 4; 506(3): 209–19PubMedCrossRefGoogle Scholar
  86. 86.
    Silvestre JS, Prous J. Research on adverse drug events: I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol 2005 Jun; 27(5): 289–304PubMedCrossRefGoogle Scholar
  87. 87.
    Citrome L. Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opin Drug Metab Toxicol 2010; 6(12): 1551–64PubMedCrossRefGoogle Scholar
  88. 88.
    Bishara D, Taylor D. Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder. Neuropsychiatr Dis Treat 2009; 5: 483–90PubMedGoogle Scholar
  89. 89.
    Bishara D. Once-monthly paliperidone injection for the treatment of schizophrenia. Neuropsychiatr Dis Treat 2010 Sep 7; 6: 561–72PubMedCrossRefGoogle Scholar
  90. 90.
    Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008 Jan; 13(1): 27–35PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Marc De Hert
    • 1
  • Weiping Yu
    • 1
  • Johan Detraux
    • 1
  • Kim Sweers
    • 1
  • Ruud van Winkel
    • 1
    • 2
  • Christoph U. Correll
    • 3
    • 4
    • 5
    • 6
  1. 1.University Psychiatric CentreCatholic University LeuvenKortenbergBelgium
  2. 2.Department of Psychiatry and Neuropsychology, EURON, South Limburg Mental Health Research and Teaching NetworkMaastricht University Medical CentreMaastrichtThe Netherlands
  3. 3.Psychiatry Research, North Shore — Long Island Jewish Health SystemThe Zucker Hillside HospitalGlen OaksUSA
  4. 4.Albert Einstein College of MedicineBronxUSA
  5. 5.The Feinstein Institute for Medical ResearchManhassetUSA
  6. 6.Hofstra North Shore-LIJ School of MedicineHempsteadUSA

Personalised recommendations